These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 30799638)

  • 1. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
    J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
    Reich K; Pinter A; Lacour JP; Ferrandiz C; Micali G; French LE; Lomaga M; Dutronc Y; Henneges C; Wilhelm S; Hartz S; Paul C;
    Br J Dermatol; 2017 Oct; 177(4):1014-1023. PubMed ID: 28542874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A
    Puig L; Zhu B; Burge R; Shrom D; Dong Y; Shen W; Mallbris L; Reich K
    J Clin Aesthet Dermatol; 2020 Oct; 13(10):18-22. PubMed ID: 33584952
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
    Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
    Wasel N; Thaçi D; French LE; Conrad C; Dutronc Y; Gallo G; Berggren L; Lacour JP
    Dermatol Ther (Heidelb); 2020 Aug; 10(4):663-670. PubMed ID: 32415575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.
    Paul C; Guenther L; Torii H; Sofen H; Burge R; Lin CY; Potts Bleakman A; Mallbris L; Poulin Y
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):68-72. PubMed ID: 28881462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
    Leonardi C; Maari C; Philipp S; Goldblum O; Zhang L; Burkhardt N; Ball S; Mallbris L; Gonzalez P; Fernández-Peñas P; Puig L
    J Am Acad Dermatol; 2018 Nov; 79(5):824-830.e2. PubMed ID: 29803904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
    Blauvelt A; Muram TM; See K; Mallinckrodt CH; Crowley JJ; van de Kerkhof P
    J Dermatolog Treat; 2018 May; 29(3):220-229. PubMed ID: 28792259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
    Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
    J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
    Lebwohl MG; Gordon KB; Gallo G; Zhang L; Paul C
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):301-309. PubMed ID: 31479549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
    Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
    Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
    Paul C; Griffiths CEM; van de Kerkhof PCM; Puig L; Dutronc Y; Henneges C; Dossenbach M; Hollister K; Reich K
    J Am Acad Dermatol; 2019 Jan; 80(1):70-79.e3. PubMed ID: 29969700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.